Pancreatic cancer(PC)
Conditions
Interventions
Gold Standard:The clinical diagnosis result (with pathological diagnosis as the gold standard for pancreatic cancer
clinical diagnosis and physical examination results for benign diseases and healthy controls).
Index test:A multi-dimensional target synchronous detection method based on DLD chip–PSµm size encoding (for detecting GPC1+Exos, miR-21, and CA19-9).
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.PC Group: Voluntarily signed the informed consent form; Age >= 18 years; Diagnosed with pancreatic cancer (PC) by clinical endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), or postoperative pathological biopsy; Available residual blood samples from routine clinical laboratory tests completed before undergoing surgery, radiotherapy, or chemotherapy. 2.Patients with Benign Pancreatic/Biliary Diseases: Voluntarily signed the informed consent form; Age >= 18 years; Diagnosed with benign pancreatic or biliary diseases (such as chronic pancreatitis, gallstones, cholecystitis, choledocholithiasis, etc.) by clinical imaging examinations (e.g., CT, MRI, ultrasound) and laboratory tests, with no evidence of malignant tumor; Available residual blood samples from routine clinical laboratory tests completed before routine diagnosis and treatment. 3.Healthy Subjects: Voluntarily signed the informed consent form; Age >= 18 years; No diagnosed disease; Available residual blood sample from routine clinical laboratory tests completed during health check-ups.
Exclusion criteria
Exclusion criteria: 1.PC Group: Concomitant with other malignant tumors; Having undergone surgery, radiotherapy, or chemotherapy; Complicated with severe biliary obstruction or biliary system infection; Suffering from other chronic diseases; Incomplete serum marker testing; Judged by the investigator as unsuitable for participation in this study. 2.Patients with Benign Pancreatic/Biliary Diseases: Having received routine diagnosis and treatment; Suffering from malignant tumor; Complicated with severe biliary obstruction or biliary system infection; Suffering from other chronic diseases; Incomplete serum marker testing; Judged by the investigator as unsuitable for participation in this study. 3.Healthy Subjects: Incomplete serum marker testing; Suffering from chronic disease; Judged by the investigator as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity;Accuracy; | — |
Countries
China
Contacts
Public ContactZhang Yuqin
Southern Medical University Southern Hospital
Outcome results
None listed